Omeros (OMER) Cash & Equivalents (2010 - 2026)
Omeros (OMER) posted Cash & Equivalents of $1.9 million for Q1 2026, down 80.27% sequentially from $9.7 million in Q4 2025, and down 55.27% YoY from $4.3 million in Q1 2025.
Analysis
Omeros (OMER) Cash & Equivalents (2010 - 2026) Analysis & Trends
Omeros has reported Cash & Equivalents for 17 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Cash & Equivalents fell 55.27% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 55.27% YoY) and the FY2025 annual result came in at $9.7 million, up 184.12% from the prior year.
- Cash & Equivalents slipped to $1.9 million in Q1 2026 per OMER's latest filing, from $9.7 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $310.3 million in Q3 2023 and troughed at $1.5 million in Q3 2024.
- A 5-year average of $48.6 million and a median of $9.0 million in 2022 frame the typical range for Cash & Equivalents.
- The widest YoY moves for Cash & Equivalents: up 5960.53% in 2024, down 99.51% in 2024.
- Over 5 years, Cash & Equivalents stood at $11.0 million in 2022, then slumped by 35.46% to $7.1 million in 2023, then sank by 52.15% to $3.4 million in 2024, then jumped by 184.12% to $9.7 million in 2025, then tumbled by 80.27% to $1.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $1.9 million, $9.7 million, and $36.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 1.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.99 Mn |
| Mar 31, 2026 | 1.91 Mn |
| Dec 31, 2025 | 9.66 Mn |
| Sep 30, 2025 | 36.10 Mn |
| Jun 30, 2025 | 28.70 Mn |
| Mar 31, 2025 | 52.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 123.20 Mn |
| Jun 30, 2024 | 158.90 Mn |
| Mar 31, 2024 | 230.30 Mn |
| Dec 31, 2023 | 7.11 Mn |
| Sep 30, 2023 | 310.30 Mn |
| Jun 30, 2023 | 341.30 Mn |
| Mar 31, 2023 | 371.40 Mn |
| Dec 31, 2022 | 11.01 Mn |
| Sep 30, 2022 | 221.00 Mn |
| Jun 30, 2022 | 122.60 Mn |
| Mar 31, 2022 | 142.20 Mn |
| Dec 31, 2021 | 100.81 Mn |
| Sep 30, 2021 | 50.40 Mn |